COPYRIGHT © DIGITAL JOURNAL INC. Sitemaps: XML / News. Digital Journal is not responsible for the content of external sites. Read more about our external linking
Las Vega (Nevada), United States //— DelveInsight’s “Heart Failure Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Heart Failure Market.
The Heart Failure Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
As per DelveInsight’s assessment, globally, about 75+ key pharma and biotech companies are working on 90+ pipeline drugs in the Heart Failure therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
Heart Failure Pipeline Analysis
The report provides insights into:
– The report provides detailed insights about emerging therapies for the treatment of Heart Failure and the aggregate therapies developed by major pharma companies.
– It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Heart Failure Treatment.
– It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
– The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
– It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Heart Failure market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Delveinsight’s Report Covers Emerging Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage products (Phase I/II and Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates
Route of Administration
Heart Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
– Intra-articular
– Intraocular
– Intrathecal
– Intravenous
– Ophthalmic
– Oral
– Parenteral
– Subcutaneous
– Topical
– Transdermal
Molecule Type
Products have been categorized under various Molecule types, such as
– Oligonucleotide
– Peptide
– Small molecule
Mechanism of Action (MOA) of the Emerging Pipeline Therapies:
– Glucagon like peptide 1 receptor agonist
– Mineralocorticoid receptor antagonist
– Cell replacement
– Metabolism stimulant
– Atrial natriuretic factor receptor A agonist
– Cardiac myosin inhibitor
– Mineralocorticoid receptor modulator
– Protein phosphatase 1 inhibitor
– Neuregulin-1 stimulant
Heart Failure Therapeutics Landscape
Considerable advances have been made in the drug treatment of heart failure over the past few decades. Spironolactone, angiotensin-converting enzyme inhibitors (ACEIs), and blockers are the only agents that have been shown to reduce heart failure mortality, and all are now widely used in the community. There are a number of agents in the early stage of development that may have a potential role in managing chronic Heart Failure.
There are approx. 75+ key companies developing therapies for Heart Failure. Currently, Eli Lilly and Company is leading the therapeutics market with its Heart Failure drug candidates in the most advanced stage of clinical development.
Some of the key companies in the Heart Failure Therapeutics Market include:
Actelion Pharmaceuticals, AliveGen, AnaCardio, Antlia Biosciences, Asklepios Biopharmaceutical, AstraZeneca, Athersys, Bayer, BenevolentAI, Berlin Cures, BIAL, BioCardia, BlueRock Therapeutics, Boryung Pharmaceutical, Bristol Myers Squibb, CardioCell, Cardior Pharmaceuticals, Cardiora, Cardurion Pharmaceuticals, Chong Kun Dang, CUORiPS, Cytokinetics, DiNAQOR, Edgewise Therapeutics, Eli Lilly and Company, Evotec SE, Fujifilm Corporation, GB Sciences, GlaxoSmithKline, HAYA Therapeutics, Heartseed, Help Therapeutics, Hyloris Pharmaceuticals, Imara Inc, Imbria Pharmaceuticals, Innolife, Intra-Cellular Therapies, InvivoSciences, Ionis Pharmaceuticals, Janssen Research & Development, Lexicon Pharmaceuticals, Merck & Co, Mesoblast Inc., Metcela, Novo Nordisk, Olatec Therapeutics, Orizuru Therapeutics, Palatin Technologies, Paradigm biopharmaceuticals, Pfizer, Precigen, Procella Therapeutics, Quantum Genomics, Recardio, Regeneron Pharmaceuticals, Relaxera, Renova Therapeutics, Ribomic, Rivus Pharmaceuticals, Roche, Salubris Biotherapeutics, Sana Biotechnology, Sardocor, scPharmaceuticals, Shanghai Hongyitang Biopharmaceutical Technology, SQ Innovation, Stealth BioTherapeutics, Sulfagenix, Tasly Pharmaceuticals, Tenaya Therapeutics, Torrent Pharmaceuticals, TreeFrog Therapeutics, Windtree Therapeutics, Zensun (Shanghai) Sci & Tech, and many others.
Heart Failure Therapies covered in the report include:
– Tirzepatide: Eli Lilly and Company
– Finerenone (BAY94-8862): Bayer
– CardiAMP Cell Therapy: BioCardia
– Firibastat: Quantum Genomics
– HU 6: Rivus Pharmaceuticals
And many more
Explore More About the Emerging Drugs and Key Companies: Heart Failure Pipeline Development Activities
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Heart Failure Current Treatment Patterns
4. Heart Failure – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Heart Failure Late-Stage Products (Phase-III)
7. Heart Failure Mid-Stage Products (Phase-II)
8. Heart Failure Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Heart Failure Discontinued Products
13. Heart Failure Product Profiles
14. Key Companies in the Heart Failure Market
15. Key Products in the Heart Failure Therapeutics Segment
16. Dormant and Discontinued Products
17. Heart Failure Unmet Needs
18. Heart Failure Future Perspectives
19. Heart Failure Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Get a Detailed Assessment into the Ongoing Clinical and Regulatory Development Activities, at: Heart Failure Therapeutic Outlook
Contact Info:
Shruti Thakur
Manager (Marketing and Branding)
Email: info@delveinsight.com
https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.